8月18日，何氏眼科主力资金净流出35.69万元，占流通市值的0.02%。近五个交易日，主力资金累计净 流出713.40万元，占流通市值的0.36%。 风险提示：股市有风险，投资需谨慎。 来源：金融界 截至2025年8月18日15时0分，何氏眼科最新股价为23.78元，较前一交易日上涨0.30元，涨幅1.28%。当 日开盘价为23.60元，最高触及23.96元，最低下探23.49元，成交量为24947手，成交额0.59亿元。 何氏眼科属于医疗服务板块，公司主营业务涵盖眼科医疗、视光服务及眼健康管理等领域。 ...

（文章来源：证券日报） 证券日报网讯爱尔眼科8月18日在互动平台回答投资者提问时表示，目前国内大多数中老年人对老花 （老视）治疗的认知程度不高，老花治疗在国内普及率极低，还处于启蒙阶段。与之对应的是，欧洲地 区对老花治疗的接受度较高，公司的欧洲子公司经验丰富，老花手术业务发展良好。为了适应人口老龄 化背景下的大量新需求，公司结合海外团队经验积极发展老年眼病诊断、老视治疗等业务，已在多地爱 尔医院开设老视门诊，并将成立老视学组，为广大中老年人群提供适宜的视觉解决方案。随着适龄段人 群支付能力的提高和对视觉品质的追求，老花诊疗未来有望持续增长。 ...

公司回答表示：谢谢您对公司的关注。目前国内大多数中老年人对老花（老视）治疗的认知程度不高， 老花治疗在国内普及率极低，还处于启蒙阶段。 与之对应的是，欧洲地区对老花治疗的接受度较高， 公司的欧洲子公司经验丰富，老花手术业务发展良好。 为了适应人口老龄化背景下的大量新需求，公 司结合海外团队经验积极发展老年眼病诊断、老视治疗等业务，已在多地爱尔医院开设老视门诊，并将 成立老视学组，为广大中老年人群提供适宜的视觉解决方案。 随着适龄段人群支付能力的提高和对视 觉品质的追求，老花诊疗未来有望持续增长。责任编辑：磐石 金融界8月18日消息，有投资者在互动平台向爱尔眼科提问：董秘你好，目前我们人口老龄化一直在加 剧，老年人口越来越多，但是目前针对老年人的视力矫正并不普及，很多人觉得老花眼没办法治疗，这 个对公司的未来业务增长相当重要，公司有没有关注到这方面的潜在需求，在这方面有没有相关的技术 储备，公司的技术储备在国际上处于什么样的水平。 ...

Core Viewpoint - The article discusses common misconceptions about myopia prevention and treatment in children, emphasizing the importance of accurate eye examinations and appropriate corrective measures. Group 1: Eye Examination Methods - Cycloplegic refraction is a standard method for assessing children's refractive errors, temporarily paralyzing the ciliary muscle to obtain accurate measurements [1] - Quick cycloplegia is suitable for children over 8 years old, using a combination of tropicamide eye drops, with a fast recovery time [1] - Slow cycloplegia, using 1% atropine ointment, is recommended for younger children, providing more accurate results but with a longer recovery time of about three weeks [1] Group 2: Myopia Treatment Guidelines - Children with myopia between 50-300 degrees may not need glasses if their naked eye vision is acceptable (0.8 or above) and they do not experience significant eye strain [2] - For moderate myopia (300-600 degrees) and high myopia (over 600 degrees), it is advised to wear corrective glasses all day to prevent further eye strain and elongation of the eyeball [2] Group 3: Importance of Regular Check-ups - Regular follow-ups every three months are essential after getting glasses to monitor changes in vision and eye axis length, allowing for timely adjustments in myopia management strategies [3] Group 4: Other Common Eye Conditions - Besides myopia, conditions like amblyopia, astigmatism, and strabismus are prevalent in children and require attention [4] - Amblyopia, if not treated by age 6-8, can lead to permanent vision impairment [5] - Astigmatism is often congenital and can be corrected through glasses or contact lenses [6] - Strabismus requires professional evaluation to determine the cause and severity for personalized treatment [7] Group 5: Myopia Prevention Misconceptions - Wearing glasses does not cause eye deformation; they are external aids and do not affect the eye's development [8] - Low-concentration atropine eye drops can slow myopia progression but cannot reverse it [9] - Corrective lenses should match the child's actual refractive error; under-correcting can lead to increased eye strain and worsen myopia [10] - Wearing appropriate glasses does not worsen myopia; in fact, not wearing them can accelerate its progression [11]

Core Viewpoint - The recent implementation of the personal consumption loan interest subsidy policy by the Ministry of Finance, the People's Bank of China, and the Financial Regulatory Administration is expected to boost consumer spending in key sectors, including healthcare, which may positively impact the ophthalmology industry [4]. Group 1: Financial Performance - In 2024, the company is projected to achieve revenue of 20.983 billion yuan (YOY +3%) and a net profit attributable to shareholders of 3.556 billion yuan (YOY +6%) [5]. - The company's core business segments show stable revenue growth, with the refractive business reaching 7.6 billion yuan (YOY +2.31%) and the optical business at 5.28 billion yuan (YOY +6.42%) [6]. Group 2: Market Outlook - The ophthalmology industry is expected to see increased demand due to the upcoming summer peak season and the rigid nature of healthcare needs, which may be further supported by the new personal consumption loan policy [5]. - The company is well-positioned as an industry leader, with a focus on high-end transformation and steady growth anticipated in 2025 [6]. Group 3: Strategic Initiatives - The company is advancing its "AI + Ophthalmology" strategy, enhancing its competitive edge both domestically and internationally [7]. - The launch of the AierGPT model and the digital human "Eyecho" aims to integrate digital technologies into ophthalmology, improving service delivery and patient engagement [8].

Core Viewpoint - The strategic cooperation agreement between Greentown Service and Aier Medical Investment Group aims to explore innovative property services in the health sector, particularly focusing on eye health management and overall wellness [1] Group 1: Company Profiles - Aier Medical Investment Group, through its subsidiary Aier Eye Hospital, is a global leader in eye health, with a service network spanning Asia, America, and Europe, emphasizing advanced technology and humanistic care [1] - Greentown Service is recognized as a leading brand in high-end property services in China, developing a comprehensive digital and integrated service model that includes property, lifestyle, and urban services supported by technology [1] Group 2: Strategic Collaboration - The collaboration reflects the alignment of Greentown Service's philosophy of sincerity, kindness, refinement, and perfection with Aier's mission to ensure eye health rights for all, regardless of wealth [1] - The partnership represents an innovative practice of the "property + medical" model, aiming to set international standards with features like ideal healing environments, humanistic healing spaces, and intelligent healing platforms [1] Group 3: Future Focus - The future focus of the collaboration will be on medical and health services, with an emphasis on solidifying foundations, specializing in core areas, expanding the overall framework, and enhancing value to create a distinctive brand [1]

Core Viewpoint - The company aims to build a comprehensive ophthalmology service platform through its "Smart Bright City" strategy, integrating advanced technologies such as big data, artificial intelligence, genetic science, and regenerative medicine to enhance eye health management across the entire lifecycle [1] Group 1 - The company is focused on creating an innovative ecosystem that covers all aspects of eye health management [1] - The establishment of an industrial fund will accelerate the company's layout in the new generation of healthcare fields, starting from eye health [1] - This strategy is expected to enhance the company's integration capabilities within the industry chain, build technological barriers, and empower downstream services [1] Group 2 - The approach aims to achieve resource sharing and complementary advantages, further stimulating innovation vitality [1] - The overall goal is to improve the company's core competitiveness in the ophthalmology sector [1]

证券日报网讯爱尔眼科（300015）8月14日在互动平台回答投资者提问时表示，公司海外布局采取"精挑 细选、稳健扩张、本土运营"的策略方针。自从中国香港开始探索出海之路，迄今已有近十年海外并购 管理经验。在欧洲地区，通过收购与新建相结合的方式，规模、收入和利润均保持良好增长势头。在东 南亚地区，以新加坡、马来西亚为基础，计划逐步拓展至人口较多的新兴市场。在英国地区，通过收购 完成初步布局，目前正通过优化管理和资源整合改善经营状况。海外业务占比近年来逐步提高，并与国 内机构实现优势互补、协同发展，通过汲取广泛经验，持续打造全生命周期眼健康服务集团。 ...

证券日报网讯 爱尔眼科（300015）8月14日在互动平台回答投资者提问时表示，近年来，近视高发化、 低龄化、高度化成为影响国民眼健康的重大问题。同时，人口老龄化也对视力矫正衍生出更多的需求和 更高的要求。多部门联合推出贴息政策实施方案，视力矫正属于健康医疗重点领域之一，患者符合条件 即可享受贴息政策。政策惠民生，有利于激发消费潜力，提升居民眼健康水平。公司将加快服务创新、 技术创新，为全年龄段人群提供多层次的全眼科诊疗服务。 ...

Group 1 - The Ministry of Finance, the People's Bank of China, and the Financial Regulatory Bureau have issued a policy to provide financial subsidies for eligible personal consumption loans, covering various sectors including home appliances, automotive, education, and healthcare [1] - The implementation of this policy is expected to boost consumer demand, particularly in the eye care sector, as the summer season approaches [2] - The company anticipates a revenue of 20.983 billion yuan in 2024, representing a year-on-year increase of 3%, with a net profit of 3.556 billion yuan, up 6% year-on-year [2] Group 2 - The company is focusing on its "AI + Ophthalmology" strategy, enhancing its competitive advantage in both domestic and international markets [3] - The company is developing "Aier AI Eye Hospitals" and has launched the AierGPT model to improve eye health services through digital technology [3] - The company has revised its profit forecasts for 2025-2026, projecting net profits of 4.128 billion yuan and 4.725 billion yuan, respectively, while maintaining a "buy" rating due to growth potential in various business segments [3]